Ahmad Nanaa

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 15

Top Topics

Acute Myeloid Leukemia

Replacement Therapy

Allogeneic Hematopoietic Stem Cell Transplantation

Top Venues

Blood cancer journal

Journal of clinical medicine

British journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Ashwin Patel, Jan Philipp Bewersdorf, Adam S DuVall, Danielle Bradshaw, Yasmin M Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Amer M Zeidan, Vamsi K Kota, Mark R Litzow
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood cancer journal 14 (1) (2024)
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Ashwin Patel, Jan Philipp Bewersdorf, Adam S DuVall, Danielle Bradshaw, Yasmin M Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Amer M Zeidan, Vamsi K Kota, Mark R Litzow
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood cancer journal 14 (1) (2024)
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Ashwin Patel, Jan Philipp Bewersdorf, Adam S DuVall, Danielle Bradshaw, Yasmin M Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Amer M Zeidan, Vamsi K Kota, Mark R Litzow
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood cancer journal 14 (1) (2024)
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Ashwin Patel, Jan Philipp Bewersdorf, Adam S DuVall, Danielle Bradshaw, Yasmin M Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Amer M Zeidan, Vamsi K Kota, Mark R Litzow
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood cancer journal 14 (1) (2024)
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Ashwin Patel, Jan Philipp Bewersdorf, Adam S DuVall, Danielle Bradshaw, Yasmin M Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Amer M Zeidan, Vamsi K Kota, Mark R Litzow
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood cancer journal 14 (1) (2024)
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Ashwin Patel, Jan Philipp Bewersdorf, Adam S DuVall, Danielle Bradshaw, Yasmin M Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Amer M Zeidan, Vamsi K Kota, Mark R Litzow
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood cancer journal 14 (1) (2024)
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Ashwin Patel, Jan Philipp Bewersdorf, Adam S DuVall, Danielle Bradshaw, Yasmin M Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Amer M Zeidan, Vamsi K Kota, Mark R Litzow
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood cancer journal 14 (1) (2024)
Talha Badar, Yenny A Moreno Vanegas, Ahmad Nanaa, James M Foran, Aref A Al-Kali, Abhishek A Mangaonkar, Hemant Murthy, Hassan B Alkhateeb, David Viswanatha, Rong He, Mithun Vinod Shah, Cecilia Arana Yi, Mark R Litzow, Naseema Gangat, Ayalew Tefferi, Mirinal S Patnaik
U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity. Blood cancer journal 13 (1) (2023)
Ahmad Nanaa, Rong He, James M Foran, Talha Badar, Naseema Gangat, Animesh D Pardanani, William J Hogan, Mark R Litzow, Mrinal Patnaik, Aref A Al-Kali, Hassan B Alkhateeb
Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients. British journal of haematology (2023)
Aref A Al-Kali, Ahmad Nanaa, David Viswanatha, Rong He, Phuong Nguyen, Dragan Jevremovic, James M Foran, Cecelia Arana Yi, Patricia T Greipp, Naseema Gangat, Mirinal S Patnaik, Ayalew Tefferi, Mark R Litzow, Abhishek A Mangaonkar, Mithun Vinod Shah, Talha Badar, Hassan B Alkhateeb
Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome. Blood cancer journal 13 (1) (2023)
Bahga Katamesh, Ahmad Nanaa, Rong He, David S Viswanatha, Phuong Nguyen, Patricia T Greipp, Kurt Bessonen, Naseema Gangat, Kebede H Begna, Abhishek A Mangaonkar, Mirinal S Patnaik, William J Hogan, Ayalew Tefferi, Mark R Litzow, Mithun Vinod Shah, Cecilia Arana-Yi, James M Foran, Talha Badar, Hassan B Alkhateeb, Aref A Al-Kali
Clinical and Prognostic Impact of STAG2 Mutations in Myeloid Neoplasms: The Mayo Clinic Experience. Blood advances (2022)
Mithun Vinod Shah, Abhishek A Mangaonkar, Kebede H Begna, Hassan B Alkhateeb, Patricia Greipp, Ahmad Nanaa, Michelle A Elliott, William Joseph Hogan, Mark R Litzow, McCullough Kristen, Ayalew Tefferi, Naseema Gangat, Mirinal S Patnaik, Aref A Al-Kali, Rong He, Dong Chen
Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms. Blood cancer journal 12 (7) (2022)
Mazen Osman, Zeynettin Akkus, Dragan Jevremovic, Phuong L Nguyen, Dana Roh, Aref Al-Kali, Mrinal M Patnaik, Ahmad Nanaa, Samia Rizk, Mohamed E Salama
Classification of Monocytes, Promonocytes and Monoblasts Using Deep Neural Network Models: An Area of Unmet Need in Diagnostic Hematopathology. Journal of clinical medicine 10 (11) (2021)
Hassan B Alkhateeb, Ahmad Nanaa, David S Viswanatha, James M Foran, Talha Badar, Lisa Sproat, Rong He, Phuong Nguyen, Dragan Jevremovic, Mohamad E Salama, Patricia Theresa Greipp, Naseema Gangat, Ayalew Tefferi, Mark R Litzow, Abhishek A Mangaonkar, Mithun Vinod Shah, Mirinal S Patnaik, Aref Al-Kali
Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms. Blood advances (2021)
Ahmad Nanaa, David Viswanatha, Zhuoer Xie, Dragan Jevremovic, Phuong Nguyen, Mohamad E Salama, Patricia Greipp, Kurt Bessonen, Naseema Gangat, Mirinal S Patnaik, Animesh Pardanani, Hassan B Alkhateeb, Mithun Vinod Shah, William Joseph Hogan, Ayalew Tefferi, Mark R Litzow, Rong He, Aref A Al-Kali
Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. Blood cancer journal 11 (6) (2021)